3D Printed Drugs Market Share, Trends, Analysis and Forecast 2023-2029

The global 3D printed drugs market is anticipated to grow at a CAGR of 9.1% during the forecast period. The key companies across the globe are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace. For instance, in March 2020, Aprecia Pharmaceuticals LLC, a 3D printed pharmaceuticals company, has announced a partnership with Purdue University. This partnership was done for the development of various projects by using Aprecia ZIpDose technology in the 3D printing of drugs. .

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/3d-printed-drugs-market

Apart from this, in April 2020, FabRx Ltd., a biotech spin-out from University College London (UCL) in the UK, has announced the launch of the M3DIMAKER system, a pharmaceutical 3D printer developed for the production of customized medicine. M3DIMAKER 3D printer is controlled by a specialized platform that allowing users to pick the dosage recommended by the pharmacist and clinician. The app also includes a data matrix reader and fingerprint access control, ensuring reliability and stability. In September 2019, the system was first launched in Switzerland at the ILMAC Exhibition and after testing, now it is available for the market.

In March 2021, CELLINK Inc, a Swedish-based 3D bioprinter manufacturer, has acquired MatTek Corp., an in-vitro technology specialist, for around $68 million. Also, in April 2021, Materialise NV, a Belgian-based 3D printing service provider, has acquired Link3D, a software development company by the end of the year 2021. This acquisition will help to remove the complexities associated with scaling 3D printing as part of a connected, industrial manufacturing process. Besides, in February 2021, Merck KGaA, a science and technology company, and AMCM, a Germany-based company, has announced the agreement on the 3D printing of tablets. Thus, the mergers & acquisitions, partnership by the major players, and new and innovative product development in the 3D printed drugs market are driving the growth during the forecast period.

Market Coverage

• The market number available for - 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered-
o By Dosage Forms
o By Technology
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Aprecia Pharmaceuticals LLC, Fabrx Ltd., GlaxoSmithKline PLC, AstraZeneca PLC, Merck KGaA, and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global 3D Printed Drugs Market Report Segment

By Dosage Forms

• Tablet
• Capsules
• Multi-Drug Implant
• Nanoparticles
• Solutions
• Nano suspension
• Encapsulated within a polymer
• Implant

By Technology

• Inkjet Printing
• Zip Dose
• Thermal Inkjet (TIJ) Printing
• Fused Deposition Modelling (FDM)
• Stereolithography (SLA)
• Others

By Application

• Dental
• Hearing & Audibility Aid
• Medical Implants
• Neurology
• Orthopedic

A full report of 3D Printed Drugs Market is available at: https://www.omrglobal.com/industry-reports/3d-printed-drugs-market

3D Printed Drugs Market- Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• 3D Systems Corp.
• Anatomics Pty Ltd
• Aprecia Pharmaceuticals, LLC
• Cycle Pharmaceuticals Ltd.
• FabRx Ltd.
• AstraZeneca Plc
• Biomedical Modeling Inc.,
• CELLINK AB
• EnvisionTEC GmbH
• GlaxoSmithKline Plc
• Linx Printing Technologies
• Materialise NV

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Visit More Report at

https://www.asiatimeskorea.com/press-release/t-%eb%a6%bc%ed%94%84%ea%b5%ac-%ed%99%9c%ec%84%b1%ed%99%94-%ed%95%ad%ec%9b%90-cd80-%ec%8b%9c%ec%9e%a5-%eb%8f%99%ed%96%a5-%ec%97%b0%ea%b5%ac-%eb%b3%b4%ea%b3%a0%ec%84%9c-%ec%84%b1%ec%9e%a5-%ea%b8%b0/326646/
https://www.diario-ya.com/regionales/%e9%85%aa%e6%b0%a8%e9%85%b8%e8%9b%8b%e7%99%bd%e6%bf%80%e9%85%b6-fyn-%e5%b8%82%e5%9c%ba%e8%b6%8b%e5%8a%bf%e3%80%81%e6%9c%aa%e6%9d%a5%e5%b1%95%e6%9c%9b%e3%80%81covid-19-%e5%bd%b1%e5%93%8d%e5%88%86/389174/
https://sportmsr.com/2029-%d8%a7%d8%aa%d8%ac%d8%a7%d9%87%d8%a7%d8%aa-%d8%b3%d9%88%d9%82-%d8%b9%d9%84%d8%a7%d8%ac-%d8%a7%d9%84%d8%af%d9%88%d8%a7%d9%84%d9%8a-%d8%8c-%d8%aa%d9%82%d8%b1%d9%8a%d8%b1-%d8%a8%d8%ad%d8%ab%d9%8a/
https://monblogapple.com/2023/02/10/tendances-du-marche-des-biomarqueurs-du-cancer-rapport-de-recherche-croissance-opportunites-et-previsions-2023-2029/
https://citytoday-hildesheim.de/index.php/2023/02/10/knochenkrebsdiagnose-und-therapeutika-marktgrose-anteil-branchenwachstum-analyse-und-prognose-2023-2029/

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.